Adverse events
The pooled estimate from two studies indicated no significant difference in the incidence of adverse events between the Infliximab and no Infliximab groups (RR= 1.09, 95% CI: 0.79 to 1.51; P = 0.51, I2 = 56%) (Figure 6)